Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its target price raised by Barclays from $47.00 to $50.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's price objective indicates a potential upside of 25.17% from the company's current price.
A number of other analysts have also recently weighed in on TEVA. Leerink Partners increased their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a research report on Thursday, November 5th. HC Wainwright reissued a "buy" rating and issued a $54.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday. TD Cowen upped their price target on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, November 4th. Argus upped their price target on Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a report on Friday, September 4th. Fourteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $48.64.
Get Our Latest Report on TEVA
Teva Pharmaceutical Industries Stock Performance
Shares of TEVA stock traded down $2.29 during trading hours on Thursday, hitting $39.95. The stock had a trading volume of 1,832,753 shares, compared to its average volume of 6,849,720. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The firm has a market capitalization of $46.55 billion, a PE ratio of 93.00, a PEG ratio of 3.69 and a beta of 0.97. The stock's 50 day moving average is $40.51 and its 200 day moving average is $35.21. Teva Pharmaceutical Industries has a twelve month low of $24.01 and a twelve month high of $44.57.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 earnings per share. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Brian Savage sold 7,342 shares of the firm's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 367,600 shares of the firm's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The SEC filing for this sale provides additional information. Insiders sold a total of 715,945 shares of company stock valued at $29,061,351 over the last ninety days. 0.54% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $33,000. Western Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $43,000. Sunbelt Securities Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $45,000. EverSource Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 64.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company's stock valued at $50,000 after purchasing an additional 647 shares in the last quarter. Finally, CX Institutional acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $54,000. Institutional investors and hedge funds own 54.05% of the company's stock.
Top Teva Pharmaceutical Industries Stories
Here are a few of the latest stories about TEVA:
- Positive Sentiment: Argus raised its price target to $50 from $42 and maintained a Buy rating, signaling greater expected upside. Argus price target article
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating; the reported target is $54. Continued bullish analyst views may support investor sentiment. HC Wainwright rating article
- Neutral Sentiment: Teva reached a settlement in states’ generic-drug price-fixing litigation. The available report does not specify the settlement terms or financial impact, so the effect on the company’s costs and remaining legal exposure is unclear. Settlement report
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.